RXi Pharmaceuticals: Interview With CEO Post-Phase 2a Interim Data
- Interview With CEO enlightens investors on current and future trials.
- RXi has many other compounds and catalysts that investors can look forward to in the coming months.
- RXi released initial data for hypertrophic scars in Phase 2a, that are promising for the future.
- RXi can use its sd-rxRNA platform and apply it to many different disease areas.